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ABSTRACT
MicroRNAs (miRNAs) that exert function by posttran-
scriptional suppression have recently brought insight in
our understanding of the role of non-protein-coding
RNAs in carcinogenesis and metastasis. In this study,
we described the function and molecular mechanism of
miR-139-5p in colorectal cancer (CRC) and its potential
clinical application in CRC. We found that miR-139-5p
was signiﬁcantly downregulated in 73.8% CRC samples
compared with adjacent noncancerous tissues (NCTs),
and decreased miR-139-5p was associated with poor
prognosis. Functional analyses demonstrated that
ectopic expression of miR-139-5p suppressed CRC cell
migration and invasion in vitro and metastasis in vivo.
Mechanistic investigations revealed that miR-139-5p
suppress CRC cell invasion and metastasis by targeting
AMFR and NOTCH1. Knockdown of the two genes phe-
nocopied the inhibitory effect of miR-139-5p on CRC
metastasis. Furthermore, the protein levels of the two
genes were upregulated in CRC samples compared with
NCTs, and inversely correlated with the miR-139-5p
expression. Increased NOTCH1 protein expression was
correlated with poor prognosis of CRC patients. Toge-
ther, our data indicate that miR-139-5p is a potential
tumor suppressor and prognostic factor for CRC, and
targeting miR-139-5p may repress the metastasis of
CRC and improve survival.
KEYWORDS miR-139-5p, AMFR, NOTCH1, colorectal
cancer, metastasis, prognosis
INTRODUCTION
MicroRNAs (miRNAs) are small endogenous non-coding
RNAs that regulate the expression of target genes at the
post-transcriptional level through sequence-speciﬁc binding
to the 3′ untranslated region (3′UTR) of their speciﬁc
mRNAs, resulting in translational inhibition even destruction
of the target mRNAs (Bartel 2004). MiRNAs play vital roles in
tumorigenesis by acting as tumor suppressors, such as let-7,
miR-143, and miR-200 (Chen et al. 2009; Li et al. 2009), or
oncogenes, such as miR-21, miR-155, and miR-95 (Asan-
gani et al. 2008; Huang et al. 2011; Hwang et al. 2014).
Deregulation of miRNAs is a common event in human
tumors and involves in various pathological processes,
possessing with either oncogenicity or promotion of metas-
tasis. Though recent researches of miRNAs have brought
mind-blowing insight into our knowledge of human cancers,
there are still largely unknown details that need to be
explored further.
Colorectal cancer (CRC) is one of the most commonly
diagnosed cancers in both genders worldwide. Over 1.2
million new cancer cases occur annually, resulting in greater
than 600,000 deaths each year (Jemal et al. 2011). Although
some advances are achieved in the diagnosis and treatment,
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the disease is very often diagnosed at an advanced stage
with tumor metastasis, making it starving for the discovery of
new metastasis relevant molecules that could help to
improve the diagnosis and prognosis.
Many studies have shown that certain miRNAs play
important roles in various processes of the metastatic
cascade, such as cell adhesion, migration, invasion,
angiogenesis, and epithelial-mesenchymal transition (EMT)
(Hurst et al. 2009; Nicoloso et al. 2009). However, detailed
mechanisms that contribute to metastasis process remain
poorly understood. Our previous data revealed that miR-
139-5p was downregulated in CRC (Huang et al. 2011).
Interestingly, decreased expression of miR-139-5p has
also been found in several other tumors, including breast
cancer, gastric cancer, hepatocellular carcinoma, glioblas-
toma, and laryngeal squamous carcinoma (Guo et al.
2009; Gu et al. 2013; Krishnan et al. 2013; Li et al. 2013;
Liu et al. 2013). Recent data suggested that miR-139 may
inhibit CRC growth and/or metastasis by targeting different
genes (Guo et al. 2012; Shen et al. 2012; Zhang et al.
2014). However, their results were contradictory. The
accurate role and clinical value of miR-139-5p in CRC
remain to be unclear. In this study, we conﬁrmed the
downregulation of miR-139-5p in an expanded CRC
cohort, which correlated with poor survival of CRC
patients, and revealed that miR-139-5p could inhibit CRC
invasion and metastasis through directly targeting AMFR
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Figure 1. miR-139-5p is frequently downregulated and associated with poor overall survival in CRC. (A) MiR-139-5p
expression was detected by quantitative reverse transcription polymerase chain reaction (qRT-PCR) in 80 paired CRC and adjacent
noncancerous tissues (NCTs). MiR-139-5p expression was markedly downregulated in tumor tissues compared with the
corresponding NCTs (U6 small nuclear RNA was used as an internal control). (B) Overall survival analysis based on the expression
level of miR-139-5p. MiR-139-5p expression was examined in 158 CRC tissues, and these cases were divided into two groups (high
or low) or four groups (1–4) based on their miR-139-5p levels in tumors. MiR-139-5p expression was positively correlated with the
overall survival.
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Decreased miR-139-5p expression is associated
with poor overall survival in CRC
Our data of miRNA expression proﬁle have demonstrated
that miR-139-5p is downregulated in CRCs compared to
NCTs (Huang et al. 2011). To further verify the result, the
expression level of miR-139-5p was examined using qRT-
PCR in an expanded cohort of 158 CRCs, including 80
tumors with paired NCTs. In accordance with the microarray
data, the results showed that miR-139-5p was downregu-
lated more than 2-fold in 73.8% of CRCs compared with
NCTs (P < 0.0001, Fig. 1A). Survival analysis showed that
high miR-139-5p expression was associated with prolonged
overall survival of CRC patients (high: the 25% highest, low:









































































































































































































































Figure 2. MiR-139-5p inhibits CRC cell migration and invasion in vitro and in vivo. (A and B) The overexpression of miR-139-5p
inhibits the migration and invasion of LoVo and HCT-116 cells. (C and D) The silencing of miR-139-5p enhanced the migration and
invasion of LoVo and HCT-116 cells. (E) The effect of miR-139 on tumor metastasis in a lung metastasis model of nude mouse. LoVo
cells stably expressing miR-139 or the control (2 × 106) were injected into the caudal vein of each nude mouse. The ectopic
expression of miR-139 signiﬁcantly reduced the number of lung metastases (*P < 0.05).
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gender, tumor size, pathologic stage, and grading, a Cox
multivariate analysis indicated that miR-139-5p expression is
an independent prognostic factor for CRC (adjusted HR =
2.681, 95% CI = 1.532–4.691, P = 0.001, Table S1). No
signiﬁcant relationship was found between miR-139-5p
expression in CRC and tumor size, location, stage, and
grading (P > 0.05).
Overexpression of miR-139-5p inhibits CRC cell
migration and invasion in vitro and metastasis in vivo
Now that miR-139-5p was downregulated in CRC and
associated with poor prognosis, we conclude that miR-139-
5p may have an inhibitory role on CRC cell proliferation and/
or invasion. To determine whether miR-139-5p could regu-
late the metastasis ability of CRC, we ﬁrst examined the
effect of miR-139-5p on CRC cell mobility. The results
showed that miR-139-5p overexpression can suppress the
cell migration and invasion (Fig. 2A and 2B), whereas
silencing of miR-139-5p promotes cell migration and inva-
sion (Fig. 2C and 2D). To identify the impact of miR-139-5p
on in vivo metastasis of CRC cells, LoVo cells stably
expressing miR-139-5p or the vector control were injected
into the caudal vein of athymic BALB/c nude mice. Ectopic
expression of miR-139-5p signiﬁcantly reduced the number
of lung metastasis sites (Fig. 2E and Table S2), further val-
idating that the invasive behaviour of CRC could be sup-
pressed by miR-139-5p. In contrast, no signiﬁcant effect of
miR-139-5p on cell proliferation was observed based on the
in vitro and in vivo analyses (Fig. S1). Because pri-miR-139
could produce both miR-139-3p and miR-139-5p, we
checked the expression and function of miR-139-3p in CRC
cells. The results showed that the expression of miR-139-3p
in CRC cells was much lower than that of miR-139-5p (Fig.
S2A and S2B), and overexpression of miR-139-3p showed
no signiﬁcant effect on CRC cell growth and migration (data
not shown). Collectively, these data indicate that miR-139-5p
was able to suppress CRC migration and invasion.
AMFR and NOTCH1 are the direct target genes of miR-
139-5p in CRC
To investigate the mechanism by which miR-139-5p exerts
anti-metastasis function in CRC, we searched for the
potential targets of miR-139-5p using bioinformatics algo-
rithms (TargetScan and miRanda) and a microarray assay.
Genomic-wide expression proﬁling was performed in NC-
and miR-139-5p-transfected LoVo cells using a microarray. A
total of 1443 downregulated transcripts (>2-fold change)
were identiﬁed in miR-139-5p-transfected cells compared
with the control (Table S3). Among the top 500 targets of
miR-139-5p predicted by the two algorithms, 31 genes were
downregulated in the miR-139-5p-transfected cells. Then, 5
potential target genes with tumor-promoting function (AMFR,
NOTCH1, HNRNPF, TOP1, and LAPTM4B) were selected
from the 31 genes and their 3′UTRs containing the
complementary binding sites of miR-139-5p were cloned into
a luciferase reporter vector to evaluate the inﬂuence of miR-
139-5p on the expression of a reporter gene using a lucif-
erase assay (Fig. 3A). The expression of the reporter gene in
the recombinant plasmids containing AMFR and NOTCH1
3′UTRs were signiﬁcantly repressed by miR-139-5p. To fur-
ther conﬁrm that AMFR and NOTCH1 are direct targets of
miR-139-5p in CRC, we mutated the predicted binding sites
of miR-139-5p in the 3′UTRs of AMFR and NOTCH1 that are
conserved among mammals, and found that the mutant
3′UTRs were completely refractory to miR-139-5p-mediated
luciferase reporter repression in HEK-293T and HCT-116
cells (Figs. 3B, 3C and S3). In line with these results, the
endogenous AMFR and NOTCH1 protein levels were also
decreased in miR-139-5p-overexpressing CRC cells and
could be restored in miR-139-5p-depleted cells (Fig. 3D).
The protein expression of AMFR and NOTCH1 is
upregulated in CRC and negatively correlated with miR-
139-5p expression
To further evaluate the relationship between miR-139-5p and
AMFR/NOTCH1, we detected their expression in paired CRC
and NCT tissues using qRT-PCR and immunohistochemistry,
respectively. Brown cytoplasmic AMFRandNOTCH1staining
was strong in CRC tissues but nearly absent in the normal
epithelia (Fig. 4A, 4B and S4). Of the 134 cases, 106 tumors
showed increased AMFR expression and 115 tumors showed
increased NOTCH1 expression compared with the paired
NCTs. The protein expression of AMFR and NOTCH in tumor
tissues inversely correlated with the miR-139-5p levels
(AMFR: Spearman r = −0.352, P = 0.0001; NOTCH1: Spear-
man r = −0.184, P = 0.033, Fig. 4C). Interestingly, a positive
correlation was observed between the protein expression of
AMFR and NOTCH1 in CRC (Spearman r = 0.986, P <
Figure 3. AMFR and NOTCH1 are the direct target genes of
miR-139-5p. (A) Initial screening of miR-139-5p target genes using
a microarray assay, bioinformatics predictions and the luciferase
reporter assay. Five downregulated genes (AMFR, NOTCH1,
HNRNPF, TOP1, and LAPTM4B) were selected from the 31 genes
in the initial screening based on the functional analysis of these
genes, and their 3′UTRs were assessed using the luciferase
reporter assay. (B and C) Analyses of the luciferase activity of the
luciferase reporter plasmids containing either wild-type (WT) or
mutant-type (MT) 3′UTRs of AMFR and NOTCH1 in HEK-293T and
HCT-116 cells. A mutation was generated in the site complementary
to the miR-139-5p seed region of the 3′UTR of AMFR or NOTCH1,
as indicated. (D) The protein levels of AMFR and NOTCH1 were
determined by Western blot assays using LoVo and HCT-116 cells
transfected with miR-139-5p mimic, miR-139-5p inhibitor (anti-miR-
139-5p) or their corresponding negative control (NC or anti-NC).
Beta-actin protein was used as an internal control.
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0.0001), suggesting that they may be regulated by same
mechanisms. Taken together, these data suggest that miR-
139-5p inactivation may result in the increased expression of
AMFR and NOTCH1 in human CRC.
Survival analyses revealed that increased NOTCH1 pro-
tein levels were associated with shorter survival time (P <
0.05, Figs. 4D and S5). After adjusting for age, gender, tumor
size, tumor grading, and tumor stage, multivariate analyses
showed that NOTCH1 expression was an independent risk
factor for survival. Tumors with higher NOTCH1 expression
(score 3) presented a higher risk of death (HR = 1.984, 95%
CI = 1.238–3.180, P = 0.004). No signiﬁcant association was
found between AMFR expression and survival.
MiR-139-5p inhibits tumor invasion via directly targeting
AMFR and NOTCH1 in CRC
To examine the functional effect of AMFR and NOTCH1 in
miR-139-5p-induced metastasis inhibition in CRC cells, we
inhibited AMFR and NOTCH1 expression with siRNA (Fig.
S6) and revealed that AMFR- and NOTCH1-depleted LoVo
cells showed decreased invasion, which phenocopied the
invasion-inhibiting effect of miR-139-5p. In contrast, the
ectopic overexpression of AMFR and NOTCH1 using plas-
mids of AMFR and NOTCH1 (ICN) ORF promoted cell
invasion, which could not be repressed by the overexpres-
sion of miR-139-5p (Fig. 5A and 5B). Taken together, these
results proved that miR-139-5p inhibits CRC invasion
through AMFR and NOTCH1.
DISCUSSION
Nowadays more than 2000 miRNAs have been identiﬁed in
human, which participate in keeping the balance of gene reg-
ulatingnetworksand regulatemore thana thirdof humangenes
at the post-transcription level (Esquela-Kerscher and Slack
2006). The disruption of microRNAs may be crucial in numer-
ous cellular processes, particularly in oncogenesis and
metastasis (Manikandan et al. 2008; Bouyssou et al. 2014).
MiR-139-5p, one of themost signiﬁcant downregulatedmiRNA
in CRC in our previous data (Huang et al. 2011), have been
identiﬁed as relating to the development of several tumor types
(Baoet al. 2011;Wonget al. 2011;Krishnanet al. 2013; Liuet al.
2013), includingCRC (Guoet al. 2012; Shen et al. 2012; Zhang
et al. 2014). Here, we identiﬁed miR-139-5p as a metastasis
inhibitor throughdirectly targetingAMFRandNOTCH1 inCRC.
MiR-139 showsextensive function in human tumorigenesis
and development. Wong ﬁrst reported that miR-139 sup-
presses metastasis and progression of hepatocellular carci-
noma by downregulating Rho-kinase 2 (Wong et al. 2011).
Bao et al. revealed that HER2 and CD44 can induce histone
deacetylation in the promoter region of the miR-139 gene,
resulting decreased miR-139 expression and increased
expression of its target CXCR4 in gastric cancer (Bao et al.
2011). Subsequent reports showed thatmiR-139-5p suppress
the invasive capability of breast cancer (Krishnan et al. 2013)
and esophageal carcinoma cells (Liu et al. 2013). These
reports indicate the common key role of miR-139-5p in cancer
metastasis. In this study, we conﬁrmed the downregulation of
miR-139-5p in CRC in an expanded cohort of CRC (Fig. 1A).
Further functional analyses demonstrated that the overex-
pression of miR-139-5p can signiﬁcantly suppress cell
migration and invasion in vitro and metastasis in vivo (Fig. 2).
These results were consistent with the results of Shen et al.
and Zhang et al. (Shen et al. 2012; Zhang et al. 2014). How-
ever, Guo et al. and Zhang et al. reported that miR-139-5p
could inhibit CRC cell growth in vitro (Guo et al. 2012; Zhang
et al. 2014), which was not observed in the study of Shen et al.
(Shen et al. 2012). We also did not observe the growth-
inhibiting function of miR-139-5p using in vitro and in vivo
assays (Fig. S1). It may be due to differentmethodology or cell
lines used in different studies. These conclusions should be
validated under the same conditions in the future work.
AMFR, located on human chromosome 16q12.2, known as
gp78, is a ubiquitin E3 ligase involved in the degradation of
proteins through the endoplasmic reticulum pathway (Fang
et al. 2001). AMFR has the pluripotency activated by AMF
involving cells adhesion, motility, and angiogenesis (Yanag-
awa et al. 2004; Chiu et al. 2008). AMF stimulates AMFR in
an autocrine manner and results in signalling cascades
relying on PKC and activates Rho-like GTPase, RhoA, and
Rac1, which enhance cell motility (Kanbe et al. 1994; Wang
et al. 2010). Several groups have shown that AMFR
upregulation correlates with more advanced tumor stage and
poor survival in stomach, lung, and breast cancer (Taniguchi
et al. 1998; Kawanishi et al. 2000; Jiang et al. 2006), and
appears to be a strong independent predictor for recurrence
in CRC (Nakamori et al. 1994). Although recent data sug-
gested that AMFR may be associated with tumorigenesis
and development, the detailed function and mechanisms of
AMFR remain unknown (Wang et al. 2010; Kho et al. 2013).
In this study, we showed, for the ﬁrst time, that AMFR was
regulated by miR-139-5p and could promote CRC invasion,
and the expression of AMFR protein was negatively corre-
lated with miR-139-5p in CRC tissues, suggesting that the
increasing activity of AMFR was due to the inactivation of
miR-139-5p in CRC (Figs. 3 and 4). The detailed mechanism
by which AMFR promotes CRC cell metastasis should be
investigated in future study.
NOTCH1 is another target gene of miR-139-5p identiﬁed
in CRC (Zhang et al. 2014). Four NOTCH receptors
(NOTCH1–4) and ﬁve ligands (Jagged-1, 2, Delta-1, 3, 4)
have been described in mammals (Miele et al. 2006). Dys-
regulated activity of NOTCH signaling is frequently observed
in human cancers and a lot of studies have suggested an
involvement of NOTCH signaling in cancer angiogenesis
and metastasis (Hellstrom et al. 2007; Hu et al. 2012).
NOTCH1 is found upregulated in CRC and correlates with
tumor proliferation, differentiation, lymphatic metastases,
and survival time (Reedijk et al. 2008; Chu et al. 2010;
Hristova et al. 2013). We observed that NOTCH1 was
directly regulated by miR-139-5p at the post-transcriptional
RESEARCH ARTICLE Mingxu Song et al.









level and promoted CRC invasion. And our data showed that
the expression of NOTCH1 was signiﬁcantly upregulated in
CRC and negatively correlated with miR-139-5p and survival
(Figs. 3 and 4). In line with our results, the metastasis-
prompting function of NOTCH1 has been reported in breast
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Figure 4. The protein expression of AMFR and NOTCH1 was upregulated in CRC and negatively correlated with miR-139-5p
expression. (A and B) Immunohistochemical staining of AMFR and NOTCH1 in CRC tissues and corresponding noncancerous
tissues (NCTs). Brown cytoplasmic AMFR/NOTCH1 staining was strong in CRC tissues but nearly absent in the normal epithelia.
AMFR and NOTCH1 protein expression were frequently increased in the tumor tissues compared with the matched NCTs. (C) The
expression levels of AMFR and NOTCH1 negatively correlated with the miR-139-5p levels in the CRC tissues. (D) Survival analysis
based on the expression levels of NOTCH1 protein. The groups were ranked according to the NOTCH1 staining intensity.
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(Wang et al. 2010; Hu et al. 2012). In addition to miR-139-5p,
other miRNAs (miR-34a, miR-144) were also reported to
inhibit NOTCH1 in CRC (Sureban et al. 2011; Bu et al. 2013),
indicating that there is a signiﬁcant cross-talk between
NOTCH and miRNAs (Mo et al. 2013).
In conclusion, we determined that miR-139-5p is down-
regulated in CRC and appears to be a prognostic factor for
CRC, and miR-139-5p inhibits CRC invasion and metastasis
by targeting AMFR and NOTCH1. These data suggest that
restoration of miR-139-5p may be a promising therapeutic
strategy for anti-metastasis treatment of CRC.
MATERIALS AND METHODS
Human tissues and cell lines
A total of 158 human primary CRC tissues and their paired adjacent
noncancerous tissues (NCTs) were collected between 2005 and
2008 at Afﬁliated Hospital of Jiangnan University and Fudan Uni-
versity Shanghai Cancer Center. The detailed clinical information for
the CRC patients is included in the Supplementary Data (Table S4).
All of the materials of patients were obtained with informed consent,
and this project was approved by the Clinical Research Ethics
Committees of the Afﬁliated Hospital of Jiangnan University and
Fudan University Shanghai Cancer Center. HEK-293T cell line and
human CRC cell lines, including HCT-8, HCT-116, LoVo, and
SW480, were purchased from American Type Culture Collection
(ATCC). HCT-8, HCT-116, and LoVo cells were cultured in RPMI-
1640, McCoy’s 5a, and F12-K medium, respectively. HEK-293T and
SW480 cells were maintained in DMEM and Leibovitz’s L-15 med-
ium, respectively. All of the media (Hyclone, USA) were supple-
mented with 10% fetal bovine serum (Gibco, USA), plus penicillin
(100 U/mL) and streptomycin (100 U/mL). The cells were incubated
under the conditions recommended by ATCC.
RNA extraction and quantitative real-time RT-PCR
Total RNA was extracted using the TRIzol reagent (Invitrogen, USA)
according to the manufacturer’s instructions. The concentration of
RNA was measured using a NanoDrop ND-1000 instrument
(NanoDrop, USA). cDNA was synthesised using the PrimeScript RT
reagent kit (TaKaRa, Japan). qPCR analyses were conducted to
quantitate mRNA relative expression using SYBR Premix Ex Taq
(TaKaRa, Japan) with beta-actin as an internal control. TaqMan
microRNA assays (Applied Biosystems, USA) were used to deter-
mine miRNA expression levels (Applied Biosystems, USA) with U6
small nuclear RNA as an internal control. The results of qPCR were
deﬁned from the threshold cycle (Ct), and relative expression levels
were calculated by using the 2-△△Ct method (Livak and Schmittgen
2001). PCR was performed using ABI 7300HT and ABI Vii7 instru-
ment (Applied Biosystems, USA). The primers used for PCR ana-
lysis were listed in the Table S5.
Vector constructs
The human pri-miR-139 sequence was ampliﬁed from normal
human genomic DNA by nested PCR using PrimerSTAR Premix
(TaKaRa, Japan). The sequence was then cloned into the lentivirus


































































































































Figure 5. MiR-139-5p inhibits CRC invasion via directly targeting AMFR and NOTCH1 in CRC. (A and B) The knockdown of
AMFR or NOTCH1 by siRNA signiﬁcantly repressed CRC cell invasion, which phenocopied the function of miR-139-5p, whereas the
overexpression of AMFR or NOTCH1 (ORF without 3′UTR) markedly promoted cell invasion and counteracted miR-139-5p-induced
invasion inhibition in LoVo cells.
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miR-139. The predicted binding sites in the 3′UTRs of the potential
target genes of miR-139-5p were ampliﬁed by nested PCR and
cloned into the region directly downstream of a CMV promoter-dri-
ven ﬁreﬂy luciferase cassette in the pcDNA3.0 vector (pLUC). The
mutant 3′UTRs of AMFR and NOTCH1, which carry the mutated
sequence in the complementary site of the seed region of miR-139-
5p, were generated from their 3′UTR-WT plasmids by overlap-
extension PCR. The sequences of the wild-type and mutant 3′UTRs
were conﬁrmed by DNA sequencing. The open reading frame (ORF)
of AMFR was ampliﬁed via nested PCR and cloned into the pWPXL
vector. The intracellular domain of the NOTCH1 (ICN) plasmid pSIN-
EF2-ICN was kindly provided by Prof. Lei Dong (State Key Labo-
ratory of Pharmaceutical Biotechnology, School of Life Sciences,
Nanjing University). The primers and endonuclease sites used for
the vector constructs are shown in the Supplementary Data (Table
S5).
Oligonucleotide transfection
MiR-139-5p mimics and inhibitors (anti-miR-139-5p, chemically
modiﬁed antisense oligonucleotides designed to speciﬁcally target
mature miR-139-5p), as well as their corresponding negative control
(NC), were synthesised at Ribobio (Guangzhou, China). AMFR and
NOTCH1 small interfering RNA (si-AMFR target sequence:
5′-GTACATACATCTCCTACAA-3′; siNOTCH1: 5′-GUCCAGGAAAC
AACUGCAATT-3′) were purchased from GenePharma (Shanghai,
China). Oligonucleotide transfection was performed using Lipofect-
amine 2000 reagents (Invitrogen, USA) according to the manufac-
turer’s instructions.
Lentivirus production and transduction
Lentivirus production and transduction was performed as described
previously (Huang et al. 2011).
Cell migration and invasion assay
For the migration assays, 1 × 105 HCT-116 or 5 × 104 LoVo cells
(stably expressed miR-139 or vector control) in 200 μL serum-free
medium were placed into the top chamber of each insert (BD Bio-
sciences, NJ), and 800 μL medium supplemented with 10% fetal
bovine serum into under chamber, After 24 (HCT-116) or 8 (LoVo) h
of incubation at 37°C, cells adhering to the lower membrane were
stained with 0.1% crystal violet containing 20% methanol, imaged,
and counted using an IX71 inverted microscope (Olympus, Japan).
For the cell invasion assay, the polycarbonate membranes of the
upper compartment of the chambers were pre-coated with a matrix
gel.
Cell proliferation assay
Cell proliferation was quantiﬁed using the Cell Counting Kit-8 (CCK8;
Dojindo Laboratories, Japan) according to the manufacturer’s
Manual as described previously (Huang et al. 2011).
Tumor formation assay in a nude mouse model
Athymic male BALB/c nude mice were feeding under speciﬁc
pathogen-free conditions in the Experimental Animal Department of
Fudan University. The assay protocols were approved by the
Shanghai Medical Experimental Animal Care Commission. For the
in vivo tumor formation assays, 4 × 106 LoVo cells stably expressing
miR-139 or the vector control were subcutaneously injected into
either ﬂank of the same athymic male BALB/c nude mouse at 5
weeks of age (n = 6 for each group). After transplantation, the growth
of the tumors was assessed twice a week. The mice were sacriﬁced
after a period of 4–6 weeks, and the weight of subcutaneous tumors
were calculated. For the in vivo metastasis assays, 2 × 106 LoVo
cells stably expressing miR-139 or the control vector were sus-
pended in 100 μL of DMEM and were injected into the caudal vein of
each nude mouse (n = 10 for each group). The nude mice were
maintained under speciﬁc pathogen-free conditions in the Experi-
mental Animal Department of Fudan University. The mice were
sacriﬁced after a period of 5 weeks.
Microarray analysis
Expression proﬁling was performed using an Agilent human whole
genome oligo microarray chip (4 × 44 K) (Agilent, USA). A total of 5 ×
105 LoVo cells were seeded in 6-cm2 tissue culture plates and
transfected with the miR-139-5p mimic or NC as described above.
After propagation for 48 h, total RNA was extracted for the expres-
sion proﬁling analyses. The microarray proﬁling was performed as
described in our previous work (Wang et al. 2014).
Luciferase assay
Approximately 5000 HEK-293T cells per well were plated into
96-well plates and were cotransfected with 50 nmol/L of miR-139-5p
mimic (or NC), 50 ng of the luciferase reporter, and 5 ng of the pRL-
CMV Renilla luciferase reporter using 0.5 µL per well Lipofectamine
2000 (Invitrogen, USA). After 48 h incubation, the ﬁreﬂy and Renilla
luciferase activities were quantiﬁed using a dual-luciferase reporter
assay (Promega, USA).
Western blot
Cellular proteins were extracted and separated in SDS-PAGE gels,
ﬁrst separated by 10% sodium dodecyl sulphate-polyacrylamide gel
electrophoresis and then transferred to nitrocellulose membranes
(Bio-Rad Laboratories, USA). The membranes were blocked with
5% nonfat milk and incubated with a mouse anti-AMFR polyclonal
antibody at a dilution of 1:500 (Abcam, USA), a rabbit anti-activated
NOTCH1 antibody (Abcam, USA), or a mouse anti-beta-actin
monoclonal antibody at a dilution of 1:1000 (Sigma, USA). The
membranes were subsequently incubated with a goat anti-mouse
horseradish peroxidase secondary antibody (Sigma, USA). The
protein complex was detected using enhanced chemiluminescence
reagents (Pierce, France).
Immunohistochemical staining
Tissue arrays were constructed using 134 paired CRC tissues and
NCTs. Immunohistochemical staining was performed on 4 μm sec-
tions of parafﬁn-embedded tissues to determine the expression level
of AMFR protein. In brief, the slides were incubated in AMFR and
NOTCH1 antibody diluted 1:200 at 4°C overnight. The subsequent
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steps were performed using the EnVision™ FLEX High pH visual-
isation system according to the manufacturer’s instructions (DAKO,
Demark). The scoring of AMFR and NOTCH1 was performed as
previous described (Tsai et al. 2007; Skrtic et al. 2010).
Statistical analyses
The results are presented as the mean values ± SEM. The data
were subjected to Student’s t-tests, the Mann-Whitney U test or the
Kruskall-Wallis test unless otherwise speciﬁed (χ2 test, Spearson’s
correlation). The overall survival curves were plotted according to
the Kaplan-Meier method, with the log-rank test applied for com-
parisons. A P value of less than 0.05 was considered statistically
signiﬁcant. SPSS 16.0 package (IBM, USA) and Graphpad prism 5.0
software (GraphPad Software, USA) were used for statistical anal-
yses and scientiﬁc graphing, respectively.
ACKNOWLEDGEMENTS
This work was supported by Grants from the National Natural Sci-
ence Foundation of China (Grant Nos. 81071791, 81000867, and
81272299) and Medical Key Professionals Program of Jiangsu
Province (RC2011031).
ABBREVIATIONS
AMFR, autocrine motility factor receptor; CRC, colorectal carcinoma;
miRNA, microRNA; qRT-PCR, quantitative reverse transcription
polymerase chain reaction; siRNA, small interfering RNA; 3′UTR,
3′ untranslated region.
COMPLIANCE WITH ETHICS GUIDELINES
Mingxu Song, Yuan Yin, Jiwei Zhang, Binbin Zhang, Zehua Bian,
Chao Quan, Leyuan Zhou, Yaling Hu, Qifeng Wang, Shujuan Ni,
Bojian Fei,, Weili Wang, Xiang Du, Dong Hua, and Zhaohui Huang
declare that they have no conﬂict of interest.
All institutional and national guidelines for the care and use of
laboratory animals were followed. All procedures followed were in
accordance with the ethical standards of the responsible committee
on human experimentation (institutional and national) and with the
Helsinki Declaration of 1975, as revised in 2000 (5). Informed
consent was obtained from all patients for being included in the
study.
OPEN ACCESS
This article is distributed under the terms of the Creative Commons
Attribution License which permits any use, distribution, and
reproduction in any medium, provided the original author(s) and
the source are credited.
REFERENCES
Asangani IA, Rasheed SA, Nikolova DA, Leupold JH, Colburn NH,
Post S, Allgayer H (2008) MicroRNA-21 (miR-21) post-transcrip-
tionally downregulates tumor suppressor Pdcd4 and stimulates
invasion, intravasation and metastasis in colorectal cancer.
Oncogene 27:2128–2136
Bao W, Fu HJ, Xie QS, Wang L, Zhang R, Guo ZY, Zhao J, Meng YL,
Ren XL, Wang T et al (2011) HER2 interacts with CD44 to up-
regulate CXCR4 via epigenetic silencing of microRNA-139 in
gastric cancer cells. Gastroenterology 141(2076–2087):e2076
Bartel DP (2004) MicroRNAs: genomics, biogenesis, mechanism,
and function. Cell 116:281–297
Bouyssou JM, Manier S, Huynh D, Issa S, Roccaro AM, Ghobrial IM
(2014) Regulation of microRNAs in cancer metastasis. Biochim
Biophys Acta 1845(2):255–265
Bu P, Chen KY, Chen JH, Wang L, Walters J, Shin YJ, Goerger JP,
Sun J, Witherspoon M, Rakhilin N et al (2013) A microRNA miR-
34a-regulated bimodal switch targets Notch in colon cancer stem
cells. Cell Stem Cell 12:602–615
Chen X, Guo X, Zhang H, Xiang Y, Chen J, Yin Y, Cai X, Wang K,
Wang G, Ba Y et al (2009) Role of miR-143 targeting KRAS in
colorectal tumorigenesis. Oncogene 28:1385–1392
Chiu CG, St-Pierre P, Nabi IR, Wiseman SM (2008) Autocrine
motility factor receptor: a clinical review. Expert Rev Anticancer
Ther 8:207–217
Chu D, Li Y, Wang W, Zhao Q, Li J, Lu Y, Li M, Dong G, Zhang H, Xie
H et al (2010) High level of Notch1 protein is associated with poor
overall survival in colorectal cancer. Ann Surg Oncol 17:1337–
1342
Esquela-Kerscher A, Slack FJ (2006) Oncomirs—microRNAs with a
role in cancer. Nat Rev Cancer 6:259–269
Fang S, Ferrone M, Yang C, Jensen JP, Tiwari S, Weissman AM
(2001) The tumor autocrine motility factor receptor, gp78, is a
ubiquitin protein ligase implicated in degradation from the
endoplasmic reticulum. Proc Natl Acad Sci USA 98:14422–
14427
Gu W, Li X, Wang J (2013) miR-139 regulates the proliferation and
invasion of hepatocellular carcinoma through the WNT/TCF-4
pathway. Oncol Rep 31(1):397–404
Guo J, Miao Y, Xiao B, Huan R, Jiang Z, Meng D, Wang Y (2009)
Differential expression of microRNA species in human gastric
cancer versus non-tumorous tissues. J Gastroenterol Hepatol
24:652–657
Guo H, Hu X, Ge S, Qian G, Zhang J (2012) Regulation of RAP1B
by miR-139 suppresses human colorectal carcinoma cell prolif-
eration. Int J Biochem Cell Biol 44:1465–1472
Hellstrom M, Phng LK, Hofmann JJ, Wallgard E, Coultas L, Lindblom
P, Alva J, Nilsson AK, Karlsson L, Gaiano N et al (2007) Dll4
signalling through Notch1 regulates formation of tip cells during
angiogenesis. Nature 445:776–780
Hristova NR, Tagscherer KE, Fassl A, Kopitz J, Roth W (2013)
Notch1-dependent regulation of p27 determines cell fate in
colorectal cancer. Int J Oncol 43:1967–1975
Hu YY, Zheng MH, Zhang R, Liang YM, Han H (2012) Notch
signaling pathway and cancer metastasis. Adv Exp Med Biol
727:186–198
Huang Z, Huang S, Wang Q, Liang L, Ni S, Wang L, Sheng W, He X,
Du X (2011) MicroRNA-95 promotes cell proliferation and targets
sorting Nexin 1 in human colorectal carcinoma. Cancer Res
71:2582–2589
RESEARCH ARTICLE Mingxu Song et al.









Hurst DR, Edmonds MD, Welch DR (2009) Metastamir: the ﬁeld of
metastasis-regulatory microRNA is spreading. Cancer Res
69:7495–7498
Hwang WL, Jiang JK, Yang SH, Huang TS, Lan HY, Teng HW, Yang
CY, Tsai YP, Lin CH, Wang HW et al (2014) MicroRNA-146a
directs the symmetric division of Snail-dominant colorectal cancer
stem cells. Nat Cell Biol 16:268–280
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011)
Global cancer statistics. CA Cancer J Clin 61:69–90
Jiang WG, Raz A, Douglas-Jones A, Mansel RE (2006) Expression
of autocrine motility factor (AMF) and its receptor, AMFR, in
human breast cancer. J Histochem Cytochem 54:231–241
Kanbe K, Chigira M, Watanabe H (1994) Effects of protein kinase
inhibitors on the cell motility stimulated by autocrine motility
factor. Biochim Biophys Acta 1222:395–399
Kawanishi K, Doki Y, Shiozaki H, Yano M, Inoue M, Fukuchi N,
Utsunomiya T, Watanabe H, Monden M (2000) Correla-
tion between loss of E-cadherin expression and overexpression
of autocrine motility factor receptor in association with pro-
gression of human gastric cancers. Am J Clin Pathol 113:266–
274
Kho DH, Nangia-Makker P, Balan V, Hogan V, Tait L, Wang Y,
Raz A (2013) Autocrine motility factor promotes HER2 cleav-
age and signaling in breast cancer cells. Cancer Res 73:1411–
1419
Krishnan K, Steptoe AL, Martin HC, Pattabiraman DR, Nones K,
Waddell N, Mariasegaram M, Simpson PT, Lakhani SR, Vlassov
A et al (2013) miR-139-5p is a regulator of metastatic pathways in
breast cancer. RNA 19:1767–1780
Li Y, VandenBoom TG 2nd, Kong D, Wang Z, Ali S, Philip PA, Sarkar
FH (2009) Up-regulation of miR-200 and let-7 by natural agents
leads to the reversal of epithelial-to-mesenchymal transition in
gemcitabine-resistant pancreatic cancer cells. Cancer Res
69:6704–6712
Li RY, Chen LC, Zhang HY, Du WZ, Feng Y, Wang HB, Wen JQ, Liu
X, Li XF, Sun Y et al (2013) MiR-139 inhibits Mcl-1 expression
and potentiates TMZ-induced apoptosis in glioma. CNS Neurosci
Ther 19:477–483
Liu R, Yang M, Meng Y, Liao J, Sheng J, Pu Y, Yin L, Kim SJ (2013)
Tumor-suppressive function of miR-139-5p in esophageal squa-
mous cell carcinoma. PLoS One 8:e77068
Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression
data using real-time quantitative PCR and the 2(-Delta Delta C
(T)) Method. Methods 25:402–408
Manikandan J, Aarthi JJ, Kumar SD, Pushparaj PN (2008) Oncom-
irs: the potential role of non-coding microRNAs in understanding
cancer. Bioinformation 2:330–334
Miele L, Golde T, Osborne B (2006) Notch signaling in cancer. Curr
Mol Med 6:905–918
Mo YY, Tang H, Miele L (2013) Notch-associated microRNAs in
cancer. Curr Drug Targets 14:1157–1166
Nakamori S, Watanabe H, Kameyama M, Imaoka S, Furukawa H,
Ishikawa O, Sasaki Y, Kabuto T, Raz A (1994) Expression of
autocrine motility factor receptor in colorectal cancer as a
predictor for disease recurrence. Cancer 74:1855–1862
Nicoloso MS, Spizzo R, Shimizu M, Rossi S, Calin GA (2009)
MicroRNAs–the micro steering wheel of tumour metastases. Nat
Rev Cancer 9:293–302
Reedijk M, Odorcic S, Zhang H, Chetty R, Tennert C, Dickson BC,
Lockwood G, Gallinger S, Egan SE (2008) Activation of Notch
signaling in human colon adenocarcinoma. Int J Oncol 33:1223–
1229
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin P, Lu Y, Li Q, Liu J (2012)
MiR-139 inhibits invasion and metastasis of colorectal cancer by
targeting the type I insulin-like growth factor receptor. Biochem
Pharmacol 84:320–330
Skrtic A, Korac P, Kristo DR, Ajdukovic Stojisavljevic R, Ivankovic D,
Dominis M (2010) Immunohistochemical analysis of NOTCH1
and JAGGED1 expression in multiple myeloma and monoclonal
gammopathy of undetermined signiﬁcance. Hum Pathol
41:1702–1710
Sureban SM, May R, Mondalek FG, Qu D, Ponnurangam S,
Pantazis P, Anant S, Ramanujam RP, Houchen CW (2011)
Nanoparticle-based delivery of siDCAMKL-1 increases microR-
NA-144 and inhibits colorectal cancer tumor growth via a Notch-1
dependent mechanism. J Nanobiotechnol 9:40
Taniguchi K, Yonemura Y, Nojima N, Hirono Y, Fushida S, Fujimura
T, Miwa K, Endo Y, Yamamoto H, Watanabe H (1998) The
relation between the growth patterns of gastric carcinoma and the
expression of hepatocyte growth factor receptor (c-met), auto-
crine motility factor receptor, and urokinase-type plasminogen
activator receptor. Cancer 82:2112–2122
Tsai YC, Mendoza A, Mariano JM, Zhou M, Kostova Z, Chen B,
Veenstra T, Hewitt SM, Helman LJ, Khanna C et al (2007) The
ubiquitin ligase gp78 promotes sarcoma metastasis by targeting
KAI1 for degradation. Nat Med 13:1504–1509
Wang L, Hou G, Xue L, Li J, Wei P, Xu P (2010) Autocrine motility
factor receptor signaling pathway promotes cell invasion via
activation of ROCK-2 in esophageal squamous cell cancer cells.
Cancer Invest 28:993–1003
Wang Q, Huang Z, Guo W, Ni S, Xiao X, Wang L, Huang D, Tan C,
Xu Q, Zha R et al (2014) MicroRNA-202-3p Inhibits Cell
Proliferation by Targeting ADP-Ribosylation Factor-like 5A in
Human Colorectal Carcinoma. Clin Cancer Res 20:1146–1157
Wong CC, Wong CM, Tung EK, Au SL, Lee JM, Poon RT, Man K, Ng
IO (2011) The microRNA miR-139 suppresses metastasis and
progression of hepatocellular carcinoma by down-regulating Rho-
kinase 2. Gastroenterology 140:322–331
Yanagawa T, Funasaka T, Tsutsumi S, Watanabe H, Raz A (2004)
Novel roles of the autocrine motility factor/phosphoglucose
isomerase in tumor malignancy. Endocr Relat Cancer 11:749–
759
Zhang L, Dong Y, Zhu N, Tsoi H, Zhao Z, Wu CW, Wang K, Zheng S,
Ng SS, Chan FK et al (2014) microRNA-139-5p exerts tumor
suppressor function by targeting NOTCH1 in colorectal cancer.
Mol Cancer 13:124
MiR-139-5p targets AMFR and NOTCH1 in colorectal cancer RESEARCH ARTICLE
© The Author(s) 2014. This article is published with open access at Springerlink.com and journal.hep.com.cn 861
P
ro
te
in
&
C
e
ll
